Samsung reports 97.66% tendered shares in provisional PolyPeptide offer result
Company / institutional announcement · Samsung Biologics
Source published: · Event / reporting date: 2026-11-02
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What changed
Samsung Biologics reported that 97.66% of PolyPeptide's issued shares had been tendered by October 30, with a provisional participation rate of 97.99% including concert parties. Its November 2 notice postponed settlement and anticipated completion in late 2026 or the first quarter of 2027, subject to remaining offer conditions and regulatory approvals.
Why it may matter
Analysis: The pending transaction could reshape peptide CDMO ownership; tender acceptance must be distinguished from completed control transfer and integration.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections